Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Scheinberg
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eureka Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Eureka Therapeutics is a joint-owner with Memorial Sloan Kettering Cancer Center of the antibodies recognizing/binding WT-1 petide/HLA-A-2”. Dr. Scheinberg has a consulting agreement with Eureka and is compensated in equity. The business of Eureka Therapeutics overlaps with the focus of Project 5.
Immunobiology for Marrow Allografts for Leukemia
Research conducted in this program should ultimately lead to improvements in results of allogeneic HSCT for acute leukemia and MDS, through reductions in acute toxicities, infection and relapse. The new drugs, antibody and cell based immuno therapies and vaccines may also be broadly applied to patients with other types of cancer, to enhance treatment effectiveness, reduce toxicities and infectious complications, and stimulate tumor resistance.
Filed on November 20, 2018.
Tell us what you know about David Scheinberg's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Scheinberg”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Scheinberg | Sloan Kettering Inst Can Research | Conflict of Interest | Sellas Life Sciences Group | $40,000 - $59,999 |
| David Scheinberg | Sloan Kettering Inst Can Research | Conflict of Interest | Novartis | $400,000 - $449,999 |
| David Scheinberg | Sloan Kettering Inst Can Research | Conflict of Interest | Eureka Therapeutics | Value cannot be readily determined |
| David Scheinberg | Sloan Kettering Inst Can Research | Conflict of Interest | Novartis | $400,000 - $449,999 |
| David Scheinberg | Sloan Kettering Inst Can Research | Conflict of Interest | Sellas Life Sciences Group | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.